Google, Constellation Energy Deal; SpaceX Rises on Talks with NASA | Stock Movers

Option Care Health shares jumped after the Financial Times reported that McKesson and Clayton, Dubilier & Rice were nearing a deal valuing the infusion-services provider at more than $5 billion including debt. Constellation Energy shares rose after Google and Constellation announced a long-term deal for 890 MW of new nuclear capacity on the PJM grid in Illinois, Pennsylvania and New Jersey. Bloomberg reported that NASA was close to announcing a bulk rocket-launch purchase tied to its $30 billion plan for a permanent human base on the moon; SpaceX was the most actively traded stock in premarket trading.

Analysis

The OPCH move is now an event-risk trade, not a clean read-through to operating value: until a definitive agreement, consideration, financing and closing conditions are disclosed, the reported valuation is not a floor. A signed deal could crystallize value, but a failed process risks a sharp giveback; MCK’s strategic rationale is plausible, while the return to MCK depends on price, funding and integration economics not yet available. Private-equity participation does not by itself establish the buyer’s final terms.

For CEG, the contract’s strategic value may exceed its near-term earnings contribution: long-dated nuclear supply can improve the economics of serving large, firm-power customers and strengthen CEG’s position in power-constrained markets. But the headline capacity is not equivalent to near-term generation or profit. Contract pricing, construction/operating responsibilities, regulatory approvals and delivery schedule determine whether value accrues to CEG or is offset by costs. Google benefits from a potential firm-power pathway for data-center growth, but the deal’s scale and economics remain unverified. Nuclear competitors such as Vistra and Talen could receive sympathy valuation support without equivalent contract economics.

NASA procurement would support launch-demand visibility if a bulk award is actually announced, but concentration in government contracts and mission timing leave execution and award risk. SpaceX is not among the supplied listed-company identities, so this is not a direct listed-equity trade; aerospace proxies may offer weak exposure.

Near term, avoid chasing announcement-driven gaps. Over 1–3 months, definitive OPCH terms and CEG contract disclosures are the key catalysts; over 6–18 months, nuclear delivery timelines, power-market conditions and actual launch cadence matter. The contrarian risk is treating capacity and headline deal values as earnings today.

Key Decisions for Investors

• OPCH: Do not chase the gap on a reported, uncompleted transaction. Reassess only after definitive price, financing, conditions and expected closing timing are public; a broken process is the principal downside catalyst.
• MCK: Treat as watch-only pending purchase economics and funding details. Falsify the strategic-positive view if the final terms imply material balance-sheet strain or the company signals weak expected returns.
• CEG: No immediate trade on capacity headlines alone. Monitor contract pricing, delivery milestones, capex/operating obligations and regulatory approvals; consider a relative long versus a broad regulated-utility exposure only if disclosures show attractive incremental economics. Revisit if approvals slip or expected delivery is pushed out.
• SpaceX/NASA: Wait for an actual award and terms before treating the procurement story as a demand catalyst. Track award size, mission schedule and launch cadence; do not use unrelated listed aerospace names as direct substitutes without evidence of revenue exposure.